20931-50-4

Usage

Uses

Used in Fragrance Industry:
2,2,6,6-TetraMethyltetrahydro-2H-pyran-4-ol is used as a fragrance ingredient for its pleasant scent, enhancing the aroma of products such as perfumes, lotions, and soaps.
Used in Food Industry:
In the food industry, 2,2,6,6-TetraMethyltetrahydro-2H-pyran-4-ol is used as a flavoring agent to impart or enhance the taste of various food products.
Used in Industrial Processes:
2,2,6,6-TetraMethyltetrahydro-2H-pyran-4-ol is utilized as a solvent in some industrial applications, taking advantage of its properties to dissolve or carry other substances in manufacturing processes.
It is important to handle and use THTP according to safety guidelines to minimize any potential risks associated with its use.

Upstream product

• 1197-66-6 2,2,6,6-tetramethyltetrahydropyran-4-one 

Downstream Products

• 1567402-47-4 5-(4-chlorophenyl)-1-(2-methoxyphenyl)-3-((2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)oxy)-1H-pyrazole 

Relevant academic research and scientific papers

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.

PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and R2 are defined herein.

SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, ring A, and G are defined herein.